Enliven Therapeutics (ELVN)

• Market cap: $1.51B
• 1 day: -2.98%
• 5 days: -8.47%
• 1 month: 59.22%
• 3 months: 17.77%
• 6 months: 22.79%
• Year to date: 63.32%
• 1 year: 20.63%
• 5 years: -51.38%
• 10 years: -57.7%
• Sector: Healthcare
• Industry: Biotechnology

About: Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

Employees: 65